Drugs that contain Darunavir
1. Prezista patents expiration
PREZISTA's oppositions filed in EPO
PREZISTA Litigations
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US6335460 | JANSSEN PRODS | α-and β-amino acid hydroxyethlamino sulfonamides useful as retroviral protease inhibitors |
Aug, 2012
(11 years ago) | |
| US6248775 | JANSSEN PRODS | α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors |
Aug, 2014
(9 years ago) | |
| USRE43596 | JANSSEN PRODS | α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors |
May, 2017
(6 years ago) | |
| US8518987 | JANSSEN PRODS | Pseudopolymorphic forms of a HIV protease inhibitor |
Feb, 2024
(2 months ago) | |
| US7700645 | JANSSEN PRODS | Pseudopolymorphic forms of a HIV protease inhibitor |
Dec, 2026
(2 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US6335460 (Pediatric) | JANSSEN PRODS | α-and β-amino acid hydroxyethlamino sulfonamides useful as retroviral protease inhibitors |
Feb, 2013
(11 years ago) | |
|
US6248775 (Pediatric) | JANSSEN PRODS | α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors |
Feb, 2015
(9 years ago) | |
| US5843946 | JANSSEN PRODS | α-and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors |
Dec, 2015
(8 years ago) | |
|
US5843946 (Pediatric) | JANSSEN PRODS | α-and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors |
Jun, 2016
(7 years ago) | |
| US6703403 | JANSSEN PRODS | Method for improving pharmacokinetics |
Jun, 2016
(7 years ago) | |
| US6037157 | JANSSEN PRODS | Method for improving pharmacokinetics |
Jun, 2016
(7 years ago) | |
| USRE43802 | JANSSEN PRODS | α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors |
Oct, 2016
(7 years ago) | |
| USRE42889 | JANSSEN PRODS | α- and β- amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors |
Oct, 2016
(7 years ago) | |
|
US6037157 (Pediatric) | JANSSEN PRODS | Method for improving pharmacokinetics |
Dec, 2016
(7 years ago) | |
|
US6703403 (Pediatric) | JANSSEN PRODS | Method for improving pharmacokinetics |
Dec, 2016
(7 years ago) | |
|
USRE42889 (Pediatric) | JANSSEN PRODS | α- and β- amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors |
Apr, 2017
(7 years ago) | |
|
USRE43802 (Pediatric) | JANSSEN PRODS | α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors |
Apr, 2017
(7 years ago) | |
|
USRE43596 (Pediatric) | JANSSEN PRODS | α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors |
Nov, 2017
(6 years ago) | |
| US8597876 | JANSSEN PRODS | Method of treating HIV infection |
Jun, 2019
(4 years ago) | |
| US7470506 | JANSSEN PRODS | Fitness assay and associated methods |
Jun, 2019
(4 years ago) | |
| US9889115 | JANSSEN PRODS | Fitness assay and associated methods |
Jun, 2019
(4 years ago) | |
|
US8597876 (Pediatric) | JANSSEN PRODS | Method of treating HIV infection |
Dec, 2019
(4 years ago) | |
|
US7470506 (Pediatric) | JANSSEN PRODS | Fitness assay and associated methods |
Dec, 2019
(4 years ago) | |
|
US9889115 (Pediatric) | JANSSEN PRODS | Fitness assay and associated methods |
Dec, 2019
(4 years ago) | |
|
US8518987 (Pediatric) | JANSSEN PRODS | Pseudopolymorphic forms of a HIV protease inhibitor |
Aug, 2024
(3 months from now) | |
|
US7700645 (Pediatric) | JANSSEN PRODS | Pseudopolymorphic forms of a HIV protease inhibitor |
Jun, 2027
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Dosing Schedule(D-119) | Dec 18, 2011 |
| New Strength(NS) | Dec 18, 2011 |
| New Indication(I-578) | Oct 21, 2011 |
| New Dosing Schedule(D-118) | Oct 21, 2011 |
| New Dosing Schedule(D-135) | Feb 01, 2016 |
| New Patient Population(NPP) | Dec 16, 2014 |
| Pediatric Exclusivity(PED) | Jun 13, 2014 |
| New Dosing Schedule(D-129) | Dec 13, 2013 |
Market Authorisation Date: 18 December, 2008
Treatment: Treatment of human immunodeficiency virus (hiv) infection in adult patients, and treatment of human immunodeficiency virus (hiv) in pediatric patients 6 years of age and older; Treatment of hiv-1 infe...
Dosage: TABLET;ORAL; SUSPENSION;ORAL
How can I launch a generic of PREZISTA before it's drug patent expiration?
More Information on Dosage
PREZISTA family patents
